New share issue in Bluefish heavily oversubscribed

The Swedish company Bluefish which licenses, manufactures and sells generic pharmaceuticals has closed a successful funding round of 25 million Skr. The share issue attracted great interest and was heavily oversubscribed. Some of the new investors include SEB Generic Pharma Fund, Catella Fonder, Mangold Fonder, BP Fonder, Carl Palmstierna and Coeli Fonder.

- Now we can move up another gear, says CEO Karl Karlsson. The company is developing as planned and we aim now to further broaden our product portfolio.

Amongst the new investors is the SEB Generic Pharma Fund.

- We believe that generic drugs form one of the most interesting parts of the global pharmaceutical industry. It is also growing faster than big pharmas, says Meelis Angerma, fund manager at SEB Generic Pharma Fund.
Bluefish is aiming at listing the company during the year to come.

Bluefish pharmaceuticals are manufactured in India where Bluefish has a wholly-owned subsidiary. The company currently has nine products that have been approved or are awaiting regulatory approval in the EU.
Saxon & Partners have been financial advisors to the company during the latest share issue.

Contact: Karl Karlsson, CEO, tel +46 8 679 50 70

Bluefish Pharmaceuticals AB is a Swedish specialty pharma company. They buy or license the rights to manufacture pharmaceuticals, mainly generic products. Low prices are maintained through efficient production and distribution. Bluefish has a wholly-owned subsidiary in Chennai, India focused on product development and production. The company is owned by the founder Karl Karlsson and a number of funds and private investors.